Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapy.
Nakalema S, Chappell CA, Pham M, Byakika-Kibwika P, Kaboggoza J, Walimbwa SI, Musaazi J, Nakijoba R, Mbabazi L, Kyohairwe I, Nassiwa S, Jeppson J, Winchester L, Siccardi M, Fletcher CV, Scarsi KK, Lamorde M. Nakalema S, et al. Among authors: musaazi j. J Antimicrob Chemother. 2022 Oct 28;77(11):3144-3152. doi: 10.1093/jac/dkac296. J Antimicrob Chemother. 2022. PMID: 36059130 Free PMC article.
Low isoniazid and rifampicin concentrations in TB/HIV co-infected patients in Uganda.
Wiltshire CS, Lamorde M, Scherrer A, Musaazi J, Corti N, Allan B, Nakijoba R, Nalwanga D, Henning L, Von Braun A, Okware S, Castelnuovo B, Kambugu A, Fehr J. Wiltshire CS, et al. Among authors: musaazi j. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19585. doi: 10.7448/IAS.17.4.19585. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394091 Free PMC article.
Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study.
Sekaggya-Wiltshire C, Castelnuovo B, von Braun A, Musaazi J, Muller D, Buzibye A, Gutteck U, Henning L, Ledergerber B, Corti N, Lamorde M, Fehr J, Kambugu A. Sekaggya-Wiltshire C, et al. Among authors: musaazi j. BMJ Open. 2017 Sep 18;7(9):e014679. doi: 10.1136/bmjopen-2016-014679. BMJ Open. 2017. PMID: 28928173 Free PMC article.
Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.
Sekaggya-Wiltshire C, von Braun A, Lamorde M, Ledergerber B, Buzibye A, Henning L, Musaazi J, Gutteck U, Denti P, de Kock M, Jetter A, Byakika-Kibwika P, Eberhard N, Matovu J, Joloba M, Muller D, Manabe YC, Kamya MR, Corti N, Kambugu A, Castelnuovo B, Fehr JS. Sekaggya-Wiltshire C, et al. Among authors: musaazi j. Clin Infect Dis. 2018 Aug 16;67(5):708-716. doi: 10.1093/cid/ciy179. Clin Infect Dis. 2018. PMID: 29514175 Free PMC article. Clinical Trial.
Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?
Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, Calcagno A, Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P. Sekaggya-Wiltshire C, et al. Among authors: musaazi j. Antimicrob Agents Chemother. 2019 May 24;63(6):e02174-18. doi: 10.1128/AAC.02174-18. Print 2019 Jun. Antimicrob Agents Chemother. 2019. PMID: 30910890 Free PMC article.
Antiretroviral concentration measurements as an additional tool to manage virologic failure in resource limited settings: a case control study.
Buzibye A, Musaazi J, von Braun A, Nanzigu S, Sekaggya-Wiltshire C, Kambugu A, Fehr J, Lamorde M, Gutteck U, Muller D, Sowinski S, Reynolds SJ, Castelnuovo B. Buzibye A, et al. Among authors: musaazi j. AIDS Res Ther. 2019 Dec 6;16(1):39. doi: 10.1186/s12981-019-0255-x. AIDS Res Ther. 2019. PMID: 31810468 Free PMC article.
Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Nabisere R, Musaazi J, Denti P, Aber F, Lamorde M, Dooley KE, Aarnoutse R, Sloan DJ, Sekaggya-Wiltshire C. Nabisere R, et al. Among authors: musaazi j. Trials. 2020 Feb 13;21(1):181. doi: 10.1186/s13063-020-4132-7. Trials. 2020. PMID: 32054536 Free PMC article.
Erratum for Sekaggya-Wiltshire et al., "Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?".
Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, Calcagno A, Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P. Sekaggya-Wiltshire C, et al. Among authors: musaazi j. Antimicrob Agents Chemother. 2020 Mar 24;64(4):e00315-20. doi: 10.1128/AAC.00315-20. Print 2020 Mar 24. Antimicrob Agents Chemother. 2020. PMID: 32209563 Free PMC article. No abstract available.
Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.
Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, Kaimal A, Mirembe G, Tukamushabe P, Ategeka G, Hakim J, Mugerwa H, Siika A, Asienzo J, Castelnuovo B, Kiragga A, Kambugu A; NADIA Trial Team. Paton NI, et al. Among authors: musaazi j. N Engl J Med. 2021 Jul 22;385(4):330-341. doi: 10.1056/NEJMoa2101609. N Engl J Med. 2021. PMID: 34289276 Clinical Trial.
65 results